nivolumab,ipilimumab
bms
['nivo']
100% orr for ipi-nivo in icis-na ve advanced markel cell carcinoma. 12-month pfs = 100%. orr drops to 31% if prior ici was used. sbrt provides no further benefit. awaiting longer fu and os data. #esmo2022 #paris 
28. MD. PhD student. Medical Oncology trainee at Ramón y Cajal University Hospital (Madrid). ES ????| EN ????| FR ????| ZH ????| ???? ??Avid traveller! ????